Drug Profile
Sorafenib nanoparticle formulation - Xspray Pharma
Alternative Names: HyNap-Sora; XS-005Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Xspray Pharma
- Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (PO, Capsule)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Cancer(In volunteers) in United Kingdom (PO, Tablet)
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in Sweden